CP
ALXN

Covenant Partners’s Alexion Pharmaceuticals ALXN Stock Holding History

Covenant Partners’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,501
Closed -$459K – 205
2021
Q2 		$459K Hold
2,501
– – 0.17% 116
2021
Q1 		$382K Sell
2,501
-1,202
-32% -$186K 0.15% 135
2020
Q4 		$579K Hold
3,703
– – 0.25% 83
2020
Q3 		$424K Sell
3,703
-628
-15% -$67.7K 0.21% 110
2020
Q2 		$486K Sell
4,331
-111
-2% -$11.8K 0.23% 100
2020
Q1 		$399K Buy
4,442
+1,293
+41% +$127K 0.21% 105
2019
Q4 		$341K Buy
3,149
+1,011
+47% +$108K 0.16% 141
2019
Q3 		$209K Sell
2,138
-2,153
-50% -$243K 0.11% 169
2019
Q2 		$562K Buy
4,291
+578
+16% +$74.5K 0.3% 87
2019
Q1 		$502K Buy
+3,713
New +$462K 0.28% 96

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return